PfizerPFEEarnings & Financial Report
Pfizer Inc. is an American multinational pharmaceutical and biotechnology corporation headquartered at The Spiral in Manhattan, New York City. Founded in 1849 in New York by German entrepreneurs Charles Pfizer (1824–1906) and Charles F. Erhart (1821–1891), Pfizer is one of the oldest pharmaceutical companies in North America.
PFE Q1 FY2026 Key Financial Metrics
Revenue
$14.5B
Gross Profit
N/A
Operating Profit
N/A
Net Profit
$2.7B
Gross Margin
N/A
Operating Margin
N/A
Net Margin
18.6%
YoY Growth
5.0%
EPS
$0.47
Pfizer Q1 FY2026 Financial Summary
Pfizer reported revenue of $14.5B (up 5.0% YoY) for Q1 FY2026, with a net profit of $2.7B (18.6% margin).
Key Financial Metrics
| Total Revenue | $14.5B |
|---|---|
| Net Profit | $2.7B |
| Gross Margin | N/A |
| Operating Margin | N/A |
| Report Period | Q1 FY2026 |
Revenue Breakdown
Pfizer Q1 FY2026 revenue of $14.5B breaks down across 3 segments, led by Product revenues at $11.7B (81.1% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Product revenues | $11.7B | 81.1% |
| Alliance revenues | $2.3B | 16.2% |
| Royalty revenues | $396.0M | 2.7% |
Pfizer Annual Revenue by Year
Pfizer annual revenue history includes year-by-year totals (for example, 2025 revenue was $62.6B).
Pfizer Quarterly Revenue & Net Profit History
Pfizer results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q1 FY2026 | $14.5B | +5.0% | $2.7B | 18.6% |
| Q4 FY2025 | $17.6B | -1.2% | $-1.6B | -9.4% |
| Q3 FY2025 | $16.7B | -5.9% | $3.5B | 21.3% |
| Q2 FY2025 | $14.7B | +10.3% | $2.9B | 19.9% |
| Q1 FY2025 | $13.7B | -7.8% | $3.0B | 21.6% |
| Q4 FY2024 | $17.8B | +34.2% | $410.0M | 2.3% |
| Q3 FY2024 | $17.7B | +39.0% | $4.5B | 25.2% |
| Q2 FY2024 | $13.3B | -27.3% | $41.0M | 0.3% |
Income Statement
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $13.28B | $17.70B | $17.76B | $13.71B | $14.65B | $16.65B | $17.56B | $14.45B |
| YoY Growth | -27.3% | 39.0% | 34.2% | -7.8% | 10.3% | -5.9% | -1.2% | 5.0% |
Balance Sheet
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $216.19B | $219.48B | $213.40B | $208.03B | $206.09B | $208.73B | $208.16B | N/A |
| Liabilities | $128.22B | $126.92B | $124.90B | $117.39B | $117.08B | $115.64B | $121.39B | N/A |
| Equity | $87.70B | $92.29B | $88.20B | $90.34B | $88.69B | $92.80B | $86.48B | N/A |
Cash Flow
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|
| Operating CF | $-1.78B | $6.71B | $6.72B | $2.33B | $-582.0M | $4.60B | $5.35B |